Abstract
The initiation and progression of tumors are closely linked to aberrant regulation of multiple genes. Among these genes, sister chromatid cohesion acetyltransferase 2 (ESCO2) has emerged as an important target in cancer research. ESCO2 exhibits complex and heterogeneous expression patterns across various types of malignancies and tumor progression stages. Extensive studies have shown that ESCO2 primarily functions in chromosomal cohesion, significantly contributing to genomic stability maintenance. Dysregulated expression of ESCO2 in tumor cells is often correlated with malignant behaviors. Given its essential role in tumorigenesis, ESCO2 has increasingly been explored as a promising therapeutic target in recent years. This review article summarizes recent research progress regarding ESCO2 in malignant tumors, aiming to identify a novel target for their treatment.